NASDAQ:RLYB Rallybio (RLYB) Stock Price, News & Analysis $15.29 -0.14 (-0.91%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$15.24 -0.05 (-0.33%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Rallybio Stock (NASDAQ:RLYB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rallybio alerts:Sign Up Key Stats Today's Range$15.07▼$15.3750-Day Range$15.29▼$17.2252-Week Range$3.67▼$17.57Volume44,037 shsAverage Volume37,832 shsMarket Capitalization$82.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Rallybio is a clinical-stage biotechnology company focused on developing treatments for people affected by rare and severe diseases. Founded in 2018, the company is based in New Haven, Connecticut, and has concentrated its research and development efforts on conditions with significant unmet medical needs. One of Rallybio’s investigational programs is RLYB212, an antibody being developed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare condition that can cause dangerously low platelet counts in a fetus or newborn. The company has also pursued other experimental therapies for rare diseases. Rallybio’s work is focused on drug research and development; its programs are investigational and are not established treatments. The company has been led by biotechnology executive and co-founder Martin Mackay.AI Generated. May Contain Errors. Read More Rallybio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreRLYB MarketRank™: 1.079098305985 of 5 starsRallybio scored higher than 22% of companies evaluated by MarketBeat, and ranked 782nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingRallybio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRallybio has only been the subject of 1 research reports in the past 90 days.Read more about Rallybio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Rallybio is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rallybio is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRallybio has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.81% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 1.18, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rallybio has recently decreased by 4.73%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRallybio does not currently pay a dividend.Dividend GrowthRallybio does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.23 News SentimentRallybio has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Rallybio this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for RLYB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows8 people have added Rallybio to their MarketBeat watchlist in the last 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rallybio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,608.00 in company stock.Percentage Held by Insiders10.30% of the stock of Rallybio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rallybio's insider trading history. Receive RLYB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RLYB Stock News HeadlinesRallybio Stock to Reverse Split on Friday, November 20th (NASDAQ:RLYB)November 12, 2026 | americanbankingnews.comCorrection to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with AvenzoNovember 11, 2026 | marketscreener.comMThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century. | Porter & Company (Ad)Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with AvenzoNovember 10, 2026 | finance.yahoo.comRallybio (RLYB) vs. Its Rivals Head-To-Head ContrastNovember 8, 2026 | americanbankingnews.comRallybio Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026October 27, 2026 | marketscreener.comMRallybio CFO Transition Amid Pending Avenzo Therapeutics MergerSeptember 9, 2026 | tipranks.comRallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBJune 2, 2026 | businesswire.comSee More Headlines RLYB Stock Analysis - Frequently Asked Questions How have RLYB shares performed this year? Rallybio's stock was trading at $5.4888 on January 1st, 2026. Since then, RLYB shares have increased by 178.6% and is now trading at $15.29. How were Rallybio's earnings last quarter? Rallybio Corporation (NASDAQ:RLYB) announced its earnings results on Tuesday, October, 27th. The company reported ($0.48) EPS for the quarter, topping analysts' consensus estimates of ($1.44) by $0.96. Rallybio had a negative net margin of 911.07% and a negative trailing twelve-month return on equity of 31.44%. When did Rallybio's stock split? Rallybio's stock reverse split on Friday, February 6th 2026.The 1-8 reverse split was announced on Tuesday, February 3rd 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 5th 2026. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Rallybio IPO? Rallybio (RLYB) raised $87 million in an initial public offering (IPO) on Wednesday, July 28th 2021. The company issued 6,200,000 shares at $13.00-$15.00 per share. How do I buy shares of Rallybio? Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rallybio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rallybio investors own include IonQ (IONQ), Joby Aviation (JOBY), Recursion Pharmaceuticals (RXRX), Acumen Pharmaceuticals (ABOS), Advanced Micro Devices (AMD), AST SpaceMobile (ASTS) and Candel Therapeutics (CADL). Company Calendar Last Earnings10/27/2026Record date for 11/30 Dividend11/05/2026Today11/18/2026Dividend Payable11/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 RLYB's financial health is in the Green zone, according to TradeSmith. RLYB has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RLYB CIK1739410 Webwww.rallybio.com Phone(203) 859-3820FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.98 million Net Margins-911.07% Pretax Margin6,500.92% Return on Equity-31.44% Return on Assets-29.89% Debt Debt-to-Equity RatioN/A Current Ratio28.87 Quick Ratio28.87 Sales & Book Value Annual Sales$860 thousand Price / Sales95.65 Cash FlowN/A Price / Cash FlowN/A Book Value$17.14 per share Price / Book0.89Miscellaneous Outstanding Shares5,380,000Free Float4,829,000Market Cap$82.26 million OptionableNot Optionable Beta-0.73 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:RLYB) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredAmerica's Biggest Bank… Down?About 4,800 Chase customers reported problems in just 15 minutes on Monday. Many couldn't log in or move money...Decentralized Masters | SponsoredYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times th...Behind the Markets | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.